Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy

PACE - Pacing and Clinical Electrophysiology

Volumn 29, Issue 7, 2006, Pages 759-764

  Grimm, Wolfram ^a,b   Plachta, Eveline ^a   Maisch, Bernhard ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Antitachycardia pacing; Implantable cardioverter defibrillator; Ventricular tachycardia

Indexed keywords

ADULT; AGED; ANTITACHYCARDIA PACING; ARTICLE; CARDIOMYOPATHY; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART PACING; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS;

CARDIAC PACING, ARTIFICIAL; CHI-SQUARE DISTRIBUTION; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 33745951462     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2006.00431.x     Document Type: Article

References (18)

1. Bardy GH, Lee KL, Mark DB, et al. For the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
2. Grimm W, Timmann U, Menz V, Hoffmann J, Funck R, Moosdorf R, Maisch B. Simplified implantation of single-lead pectoral cardioverter-defibrillators using device based testing. Am J Cardiol 1998; 81:503-506.
3. Grimm W, Hoffmann J, Müller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, asymptomatic ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002; 39:780-787.
4. Hook BG, Marchlinski FE. Value of ventricular electrogram recordings in the diagnosis of arrhythmias precipitating electrical device shock therapy. J Am Coll Cardiol 1991; 17:985-990.
5. Wathen MS, Sweeney MO, DeGroot PJ, et al. PainFREE Investigators. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104:796-801.
6. Wathen MS, DeGroot PJ, Sweeney MO, et al. PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110:2591-2596.
7. Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, Stark AJ. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: Results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005; 111:2898-2905.
8. Kouakam C, Lauwerier B, Klug D, Jarwe M, Marquie C, Lacroix D, Kacet S. Effect of elevated heart rate preceding the onset of ventricular tachycardia on antitachycardia pacing effectiveness in patients with implantable cardioverter defibrillators. Am J Cardiol 2003; 92:26-32.
9. Klein RC, Raitt MH, Wilkoff BL, et al. AVID Investigators. Analysis of implantable cardioverter defibrillator therapy in the antiarrhythmics versus implantable defibrillators (AVID) trial. J Cardiovasc Electrophysiol 2003; 14: 940-948.
10. Leitch JW, Gillis AM, Wyse DG, et al. Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy. J Am Coll Cardiol 1991; 18:145- 151.
11. Buxton AE, Sweeney MO, Wathen MS, et al. PainFREE Rx II Investigators. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverterdefibrillators. J Am Coll Cardiol 2005; 46:310-316.
12. Neuzner J, Liebrich A, Jung J, et al. Safety and efficacy of implantable defibrillator therapy with programmed shock energy at twice the augmented step-down defibrillation threshold: Results of the prospective, randomized, multicenter low-energy Endotak trial. Am J Cardiol 1999; 83:34D-39D.
13. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 2004; 15:1002-1009.
14. Kouakam C, Lauwerier B, Klug D, Jarwe M, Marquie C, Lacroix D, Kacet S. Effect of elevated heart rate preceding the onset of ventricular tachycardia on antitachycardia pacing effectiveness in patients with implantable cardioverter defibrillators. Am J Cardiol 2003; 92:26-32.
15. Bardy GH, Yee R, Jung W. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active can investigators. J Am Coll Cardiol 1996; 28:400-410.
16. Schaumann A, von zur Mühlen F, Herse B, Gonska BD, Kreutzer H. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators. A prospective study including 200 patients. Circulation 1998; 97:66-74.
17. Peters RW, Zhang X, Gold MR. Clinical predictors and efficacy of antitachycardia pacing in patients with implantable defibrillators: The importance of patient's sex. Pacing Clin Electrophysiol 2001; 24:70-74.
18. Peinado R, Almendral J, Rius T, et al. Randomized, prospective comparison of four burst pacing algorithms for spontaneous ventricular tachycardia. Am J Cardiol 1998; 82:1422-1425.